Associated Papers
Deciphering lung adenocarcinoma evolution and the role of LINE-1 retrotransposition.
Zhang T et al.
Biorxiv : the Preprint Server for Biology, 2025
40161734 (PubMed )
Supplement: media-2.xlsx › Supplementary_Table_4
Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC.
Shiller M et al.
Frontiers in Oncology, 2024
39703851 (PubMed )
Supplement: DataSheet2.xlsx › Supplemental_data
A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants.
Aboulkassim T et al.
Cell Reports, 2023
KEAP1 Cancer Mutants: A Large-Scale Molecular Dynamics Study of Protein Stability.
Wilson CJ et al.
International Journal of Molecular Sciences, 2021
The acylfulvene alkylating agent, LP-184, retains nanomolar potency in non-small cell lung cancer carrying otherwise therapy-refractory mutations.
Kulkarni A et al.
Oncotarget, 2021
33889302 (PubMed )
Supplement: oncotarget-12-791-s001.pdf
Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites.
Saigusa D et al.
Cancer Science, 2020
31828882 (PubMed )
Supplement: CAS-111-667-s002.xlsx › Table_S2
Functional significance of U2AF1 S34F mutations in lung adenocarcinomas.
Esfahani MS et al.
Nature Communications, 2019
31836708 (PubMed )
Supplement: 41467_2019_13392_MOESM4_ESM.xlsx › Sheet1
ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
Vartanian S et al.
Cancer Research, 2019
31416841 (PubMed )
Supplement: 00085472can182086-sup-204856_4_supp_5611122_ptqvbx.docx
Analysis on GENIE reveals novel recurrent variants that affect molecular diagnosis of sizable number of cancer patients.
Koyama T et al.
Bmc Cancer, 2019
30709382 (PubMed )
Supplement: 12885_2019_5313_MOESM2_ESM.xlsx › supplementary_2_filtered
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Chalmers ZR et al.
Genome Medicine, 2017
28420421 (PubMed )
Supplement: 13073_2017_424_MOESM7_ESM.xlsx › Sheet1
Molecular effects of cancer-associated somatic mutations on the structural and target recognition properties of Keap1.
Khan H et al.
The Biochemical Journal, 2015
Select heterozygous Keap1 mutations have a dominant-negative effect on wild-type Keap1 in vivo.
Suzuki T et al.
Cancer Research, 2011
Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.
Taguchi K et al.
Genes to Cells : Devoted to Molecular & Cellular Mechanisms, 2011
KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta.
Lee DF et al.
Molecular Cell, 2009
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A et al.
Plos Medicine, 2006
Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer.
Padmanabhan B et al.
Molecular Cell, 2006
Select a paper to view details